SCHEMBL518904

SCHEMBL518904

O=C(O)c1cscc1C(=O)Nc1c(F)cc(-c2cccc(OC(F)(F)F)c2)cc1F

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 20/20 0.71
NR4A2 P43354 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336887 0.88 DHODH (0.72) DHODHNR4A2
SCHEMBL517803 0.84 DHODH (0.74) DHODHNR4A2
SCHEMBL517805 0.83 DHODH (1.00) DHODHNR4A2
SCHEMBL2416890 0.82 DHODH (0.64) DHODHNR4A2
SCHEMBL1337680 0.81 DHODH (0.63) DHODH
SCHEMBL249081 0.79 DHODH (1.00) DHODHNR4A2
SCHEMBL1337733 0.76 DHODH (0.69) DHODHNR4A2
SCHEMBL1336640 0.76 DHODH (0.57) DHODHNR4A2
SCHEMBL1123965 0.75 DHODH (0.74) DHODHNR4A2
SCHEMBL14418133 0.75 DHODH (0.61) DHODHNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015154820-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS PANOPTES PHARMA GMBH (AT) 2015-10-15 WO claimed
US-8354433-B2 Anti-inflammatory agents as virostatic compounds 4SC AG (DE) 2013-01-15 US claimed
US-20230285355-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS KIORA PHARMACEUTICALS GMBH (AT) 2023-09-14 US disclosed
US-20230285355-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS KIORA PHARMACEUTICALS GMBH (AT) 2023-09-14 US disclosed
US-11730716-B2 Compounds for treating ophthalmic diseases and disorders KIORA PHARMACEUTICALS GMBH (AT) 2023-08-22 US disclosed
US-11730716-B2 Compounds for treating ophthalmic diseases and disorders KIORA PHARMACEUTICALS GMBH (AT) 2023-08-22 US disclosed
EP-2427186-B1 DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS PANOPTES PHARMA GES M B H (AT) 2022-01-12 EP disclosed
US-20210088520-A1 TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE SERVIER PHARMACEUTICALS LLC 2021-03-25 US disclosed
US-20190025313-A1 TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE SERVIER PHARMACEUTICALS LLC 2019-01-24 US disclosed
US-9795590-B2 Anti-inflammatory agents as virostatic compounds PANOPTES PHARMA GMBH (AT) 2017-10-24 US disclosed
US-9795590-B2 Anti-inflammatory agents as virostatic compounds PANOPTES PHARMA GMBH (AT) 2017-10-24 US disclosed
US-7365094-B2 Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2008-04-29 US disclosed
US-20070224672-A1 Method of Identifying Inhibitors of DHODH LEBAN JOHANN 2007-09-27 US disclosed
US-7247736-B2 Method of identifying inhibitors of DHODH 4SC AG (DE) 2007-07-24 US disclosed
US-20070027193-A1 Method of identifying inhibitors of DHODH 4SC AG (DE) 2007-02-01 US disclosed
EP-1581478-A1 DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION 4SC AG (DE) 2005-10-05 EP disclosed
EP-1578741-A1 AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2005-09-28 EP disclosed
US-20040192758-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2004-09-30 US disclosed
WO-2004056797-A1 AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2004-07-08 WO disclosed
WO-2004056747-A1 DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION 4SC AG (DE) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027193-A1 Method of identifying inhibitors of DHODH DHODH, SQOR, NDUFA5 DHODH 1/4885NR4A2 2196/4885
US-20190025313-A1 TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE DHODH, IDH1, IDH3A DHODH 1/4885NR4A2 3748/4885
US-11730716-B2 Compounds for treating ophthalmic diseases and disorders DHODH, ALDH1A2, QDPR DHODH 1/4885NR4A2 3111/4885
US-20210088520-A1 TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE DHODH, IDH1, IDH3A DHODH 1/4885NR4A2 3748/4885
US-20230285355-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS DHODH, ALDH1A2, QDPR DHODH 1/4885NR4A2 3111/4885
US-20040192758-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents PPARG, PPARD, PPARA DHODH 3023/4885NR4A2 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.